JUNSHI BIO recently announced its financial results for 2025. The company achieved operating revenue of RMB 2.498 billion, representing a year-on-year increase of 28.23%. However, the net profit attributable to owners of the parent company showed a loss of RMB 875 million, an improvement compared to the net loss of RMB 1.281 billion in the same period last year. The company has decided not to distribute any profits for the 2025 fiscal year and will not convert capital reserve into share capital. The growth in operating revenue was primarily driven by an increase in sales revenue from commercialized drugs compared to the previous year. The reduction in net loss attributable to shareholders of the listed company was also mainly due to the increased sales revenue from commercialized drugs.